文献速递胸部肿瘤

可切除非小细胞肺癌新辅助免疫检查点阻断随机对照试验中主要病理缓解和病理完全缓解作为生存替代终点的评估

Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
PubMed 文献 · J Thorac Oncol · 2024-03-08

本研究检索2017年6月至2023年10月PubMed及国际会议摘要,纳入7项随机对照试验共2385例可切除非小细胞肺癌患者,评估病理完全缓解(pCR)和主要病理缓解(MPR)作为无事件生存(EFS)和总生存(OS)替代终点的价值。患者水平上pCR和MPR与2年EFS的R²分别为0.82和0.81,与2年OS的R²分别为0.55和0.52;试验水平替代性中等但不精确,需更成熟随访及交叉数据。

要点

  • pCR和MPR与2年EFS高度相关(R²分别为0.82和0.81),但与2年OS相关性较弱(R²分别为0.55和0.52)。
  • 试验水平上,pCR和MPR的OR与EFS的HR关联R²分别为0.58和0.61,替代性中等但不精确。
  • 作者结论认为需要更成熟随访和评估研究交叉影响的数据。

核心结论

  • pCR和MPR与2年EFS呈稳健相关,但与OS无稳健相关;试验水平替代性中等但不精确,需更成熟随访及交叉影响数据。

研究设计与样本

  • 检索PubMed及国际会议摘要(2017年6月至2023年10月31日),纳入含新辅助免疫检查点阻断单药或联合化疗臂的研究。
  • 共识别7项随机临床试验,合计2385例患者。
  • 采用按样本量加权的线性回归模型分析pCR和MPR的对数OR与EFS和OS的对数HR,回归系数和R²的95%CI通过自举法计算。

主要发现

  • 患者水平:pCR与2年EFS的R²为0.82(0.66-0.94),MPR与2年EFS的R²为0.81(0.63-0.93)。
  • 按缓解状态分组的2年EFS率OR:pCR为0.12(0.07-0.19),MPR为0.11(0.05-0.22)。
  • 患者水平:pCR与2年OS的R²为0.55(0.09-0.98),MPR与2年OS的R²为0.52(0.10-0.96)。
  • 试验水平:pCR的OR与EFS的HR关联R²为0.58(0.00-0.97),MPR的OR与EFS的HR关联R²为0.61(0.00-0.97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验水平替代性中等但不精确。
  • 需要更成熟随访和评估研究交叉影响的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Controversy remains as to whether pathologic complete response (pCR) and major pathologic response (MPR) represent surrogate end points for event-free survival (EFS) and overall survival (OS) in neoadjuvant trials for resectable NSCLC. METHODS: A search of PubMed and archives of international conference abstracts was performed from June 2017 through October 31, 2023. Studies incorporating a neoadjuvant arm with immune checkpoint blockade alone or in combination with chemotherapy were included. Those not providing information regarding pCR, MPR, EFS, or OS were excluded. For trial-level surrogacy, log ORs for pCR and MPR and log hazard ratios for EFS and OS were analyzed using a linear regression model weighted by sample size. The regression coefficient and R2 with 95% confidence interval were calculated by the bootstrapping approach. RESULTS: Seven randomized clinical trials were identified for a total of 2385 patients. At the patient level, the R2 of pCR and MPR with 2-year EFS were 0.82 (0.66-0.94) and 0.81 (0.63-0.93), respectively. The OR of 2-year EFS rates by response status was 0.12 (0.07-0.19) and 0.11 (0.05-0.22), respectively. For the 2-year OS, the R2 of pCR and MPR were 0.55 (0.09-0.98) and 0.52 (0.10-0.96), respectively. At the trial level, the R2 for the association of OR for response and HR for EFS was 0.58 (0.00-0.97) and 0.61 (0.00-0.97), respectively. CONCLUSIONS: Our analyses reveal a robust correlation between pCR and MPR with 2-year EFS but not OS. Trial-level surrogacy was moderate but imprecise. More mature follow-up and data to assess the impact of study crossover are needed.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hines JB, Cameron RB, Esposito A, et al. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024. PMID: 38461929. doi:10.1016/j.jtho.2024.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。